MARKET WIREReuters • 3h ago
Iran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz - ReutersIran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz Reuters
Why RLMD Stock surged +2.69% Today — RQD Quant Desk Flash
$3.44 +2.69% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $3.45
Relmada Therapeutics Inc. (RLMD) carries a Roarable Rating of D (Sell) with 44/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D • SELL / AVOID
Cap $366.9M
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $3.45 (+0.29%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (44/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.5% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D- · Rk D+
Each axis scored 0–20
12M PRICE TARGET CONE-6.4% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for RLMD)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (44/100 Composite)
🔍 WHY RLMD SCORES 44/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+13/20 pts (30% of score)
20D Institutional Volume Accumulation (±12.5% realized swing band)
▲ #2 Bullish Driver: Macro Regime Fit+12/20 pts (27% of score)
FRED Regime × Technicals: 22% of 52W Range • RSI-14 at 52.9 (NEUTRAL RANGE)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$3.39-8.6% Next Q
36
Q2 (-2Q)Grade E$3.10+5.5% Next Q
39
Q3 (-1Q)Grade D$3.27+5.2% Next Q
41
CurrentGrade D$3.44-6.5% Hist 90D α
44
Trajectory: E (36) → D (44)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a RLMD Turnaround Squeeze
While RLMD currently carries a cautious 44/100 (D) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.84) and Max Pain ($3.61) forces dealer call-delta covering toward $8.40.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $RLMD• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “RLMD Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why RLMD Stock surged +2.69% Today — RQD Quant Desk Flash
Relmada Therapeutics Inc. (RLMD) surged +2.69% to $3.44, trading at 22% of its 52-week range ($2.15 – $8). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 22% of its 52-week range ($2.15 – $8) with RSI-14 at 52.9 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $3.44 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live RLMD Headlines & Catalysts
MARKET WIRECNBC • 5h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
MARKET WIRECNBC • 5h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 7h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 8h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 9h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 9h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 10h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring RLMD)
- ✓Walkthrough of RLMD's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
RLMD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -54.26%▲ RESISTANCE BREAKOUT
2026-10-30O $3.42H $3.65L $3.30C $3.44VOL 1.41M
RES: $3.36SUP: $2.64SMA50: $3.84SMA200: $5.36
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
RLMD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on RLMD today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for RLMD. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for RLMD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (RLMD)
Health Care Rank #510 of 1016
⚔️ SPRY vs RLMD Full Matrix →
1. Head-to-Head Health Care Peer Comparison (RLMD vs. SPRY, EBS, CYPH, GALT)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Relmada Therapeutics Inc. (RLMD) ranks #510 by composite RQD confidence (44/100, grade D) and #494 by equity capitalization ($366.9M). Within this direct 5-issuer industry benchmark cohort, EBS leads on earnings valuation at 7.0x trailing P/E, while EBS leads on capital efficiency and profitability with 8.9% ROIC and 56.1% gross margin. EBS currently holds the highest overall quantitative score in the immediate peer group at 53/100 (D+) compared with RLMD at 44/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| RLMD
ACTIVE
Relmada Therapeutics Inc. | D | 44/100 | — | — | -35.0% | +2.69% | $366.9M | Benchmark Subject |
| SPRY ARS Pharmaceuticals Inc. | E | 27/100 | — | — | -35.0% | +0.27% | $364.0M | /spry-vs-rlmd → |
| EBS Emergent BioSolutions Inc. | D+ | 53/100 | 7.0x | 56.1% | 8.9% | +1.83% | $370.2M | /ebs-vs-rlmd → |
| CYPH Cypherpunk Technologies Inc. | D- | 40/100 | 71.3x | — | -23.3% | +2.16% | $356.7M | /cyph-vs-rlmd → |
| GALT Galectin Therapeutics Inc. | D- | 42/100 | — | — | -35.0% | -0.56% | $355.8M | /galt-vs-rlmd → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2024–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001553643In its most recent audited fiscal period (FY2025, filed 2025-12-31), Relmada Therapeutics Inc. (RLMD) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of $0, operating cash flow of -$45.8M, and free cash flow of -$45.8M (+11.5% YoY). On the balance sheet, RLMD closed FY2025 with $94.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | $0 | -$45.8M | -$45.8M | $94.0M | — |
| FY2024 (FY) | 2024-12-31 | $0 | $0 | -$51.8M | -$51.8M | $45.8M | — |
3. RLMD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs RLMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Relmada Therapeutics Inc. (NASDAQ: RLMD) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $3.44 (+2.69% 1D, market cap $366.9M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, RLMD ranks #510 in composite RQD confidence.
How does RLMD compare to SPRY and EBS in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RLMD carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, SPRY (ARS Pharmaceuticals Inc.) holds a E grade (27/100 RQD, P/E N/A, ROIC -35.0%, cap $364.0M) and EBS (Emergent BioSolutions Inc.) posts a D+ grade (53/100 RQD, P/E 7.0x, ROIC 8.9%, cap $370.2M). Among the 5-stock peer group, EBS leads on earnings multiple (7.0x) while EBS leads on capital efficiency (8.9% ROIC).
What are the biggest fundamental strengths and SEC risk factors for RLMD?
Per RLMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001553643), Relmada Therapeutics Inc. generated $0 in revenue, $0 in net income, and -$45.8M in free cash flow against $94.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is RLMD trading relative to its 50-day, 200-day, and 52-week technical levels?
RLMD last traded at $3.44 (+2.69% on volume of 1,610,452 shares), positioning the stock -10.42% below its 50-day simple moving average ($3.84) and -35.82% below its 200-day simple moving average ($5.36). Across its 52-week range of $2.15 to $8.00, RLMD sits at the 22.1% percentile with a 14-day RSI of 52.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($3.01 to $3.87).
RLMD Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is RLMD stock moving today?
Why RLMD Stock surged +2.69% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.